GlycoMimetics Inc
GLYC0.157USD
0.000
Close 12/19, 16:00（ET）Quotes delayed by 15 min
10.13MMarket Cap
LossP/E TTM
More Details of GlycoMimetics Inc Company
GlycoMimetics, Inc. is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and for inflammatory diseases. It is developing a pipeline of glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in biological processes, to inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. Its drug candidates include Uproleselan, GMI-1687, Galectin Antagonists and GMI-1359. It is developing Uproleselan, a specific E-selectin antagonist, to be used in combination with chemotherapy to treat patients with AML, a life-threatening hematologic cancer, and potentially other hematologic cancers. It has designed an antagonist of E-selectin, GMI-1687, that is suitable for subcutaneous administration. GMI-1359 is a drug candidate that simultaneously targets both E-selectin and a chemokine receptor (CXCR4).
GlycoMimetics Inc Info
Ticker SymbolGLYC
Company nameGlycoMimetics Inc
IPO dateJan 10, 2014
CEO- -
Number of employees4
Security typeOrdinary Share
Fiscal year-endJan 10
Address9708 Medical Center Drive
CityROCKVILLE
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code20850
Phone12402431201
Websitehttps://glycomimetics.com/
Ticker SymbolGLYC
IPO dateJan 10, 2014
CEO- -
Company Executives of GlycoMimetics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Bruce Johnson
Mr. Bruce Johnson
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
--
--
Mr. Chinmaya Rath
Mr. Chinmaya Rath
Senior Vice President, Chief Business Officer
Senior Vice President, Chief Business Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Bruce Johnson
Mr. Bruce Johnson
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
--
--
Mr. Chinmaya Rath
Mr. Chinmaya Rath
Senior Vice President, Chief Business Officer
Senior Vice President, Chief Business Officer
--
--
Revenue Breakdown
FY2023
FY2022
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
10.00K
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Dec 15
Updated: Mon, Dec 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fairmount Funds Management LLC
19.78%
Forbion Capital Partners
12.08%
1Globe Capital, L.L.C.
10.26%
Fidelity Management & Research Company LLC
10.18%
BVF Partners L.P.
9.99%
Other
37.71%
Shareholders
Shareholders
Proportion
Fairmount Funds Management LLC
19.78%
Forbion Capital Partners
12.08%
1Globe Capital, L.L.C.
10.26%
Fidelity Management & Research Company LLC
10.18%
BVF Partners L.P.
9.99%
Other
37.71%
Shareholder Types
Shareholders
Proportion
Hedge Fund
48.18%
Venture Capital
26.39%
Investment Advisor
18.74%
Corporation
10.26%
Private Equity
5.23%
Investment Advisor/Hedge Fund
3.92%
Individual Investor
1.53%
Research Firm
1.04%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
128
11.74M
84.54%
+11.24M
2025Q2
132
3.12M
22.47%
+2.56M
2025Q1
36
604.90K
0.94%
-10.04M
2024Q4
147
32.44M
50.29%
-19.51M
2024Q3
140
23.23M
36.03%
-13.09M
2024Q2
141
28.58M
44.47%
-12.26M
2024Q1
142
39.73M
61.78%
+1.68M
2023Q4
124
37.15M
57.81%
-1.30M
2023Q3
122
36.77M
57.25%
-2.86M
2023Q2
134
37.56M
58.61%
-3.84M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fairmount Funds Management LLC
1.39M
9.99%
+1.39M
--
Jun 30, 2025
1Globe Capital, L.L.C.
896.71K
6.45%
+896.71K
--
Aug 13, 2025
Fidelity Management & Research Company LLC
1.41M
10.18%
+1.41M
--
Jun 30, 2025
BVF Partners L.P.
1.39M
9.99%
+1.29M
+1354.13%
Jun 30, 2025
VR Adviser, LLC
1.39M
9.99%
+1.36M
+4526.21%
Jun 30, 2025
Tang Capital Management, LLC
50.15K
0.36%
+50.15K
--
Jun 30, 2025
Logos Global Management LP
553.69K
3.99%
+499.69K
+925.34%
Jun 30, 2025
Boxer Capital Management, LLC
453.69K
3.27%
+453.69K
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of GlycoMimetics Inc?
The top five shareholders of GlycoMimetics Inc are:
Fairmount Funds Management LLC holds 1.39M shares, accounting for 9.99% of the total shares.
1Globe Capital, L.L.C. holds 896.71K shares, accounting for 6.45% of the total shares.
Fidelity Management & Research Company LLC holds 1.41M shares, accounting for 10.18% of the total shares.
BVF Partners L.P. holds 1.39M shares, accounting for 9.99% of the total shares.
VR Adviser, LLC holds 1.39M shares, accounting for 9.99% of the total shares.
Fairmount Funds Management LLC holds 1.39M shares, accounting for 9.99% of the total shares.
1Globe Capital, L.L.C. holds 896.71K shares, accounting for 6.45% of the total shares.
Fidelity Management & Research Company LLC holds 1.41M shares, accounting for 10.18% of the total shares.
BVF Partners L.P. holds 1.39M shares, accounting for 9.99% of the total shares.
VR Adviser, LLC holds 1.39M shares, accounting for 9.99% of the total shares.
What are the top three shareholder types of GlycoMimetics Inc?
The top three shareholder types of GlycoMimetics Inc are:
Fairmount Funds Management LLC
Forbion Capital Partners
1Globe Capital, L.L.C.
Fairmount Funds Management LLC
Forbion Capital Partners
1Globe Capital, L.L.C.
How many institutions hold shares of GlycoMimetics Inc (GLYC)?
As of 2025Q3, 128 institutions hold shares of GlycoMimetics Inc, with a combined market value of approximately 11.74M, accounting for 84.54% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 62.07%.
What is the biggest source of revenue for GlycoMimetics Inc?
In FY2023, the -- business generated the highest revenue for GlycoMimetics Inc, amounting to -- and accounting for --% of total revenue.
